The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Beximco Pharmaceuticals's current ratio for the quarter that ended in Dec. 2024 was 2.13.
Beximco Pharmaceuticals has a current ratio of 2.13. It generally indicates good short-term financial strength.
The historical rank and industry rank for Beximco Pharmaceuticals's Current Ratio or its related term are showing as below:
BXMPY'
s Current Ratio Range Over the Past 10 Years
Min: 1.02 Med: 1.52 Max: 3.15
Current: 2.13
During the past 13 years, Beximco Pharmaceuticals's highest Current Ratio was 3.15. The lowest was 1.02. And the median was 1.52.
BXMPY's Current Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 2
vs BXMPY: 2.13
Beximco Pharmaceuticals (OTCPK:BXMPY) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Beximco Pharmaceuticals Current Ratio Related Terms
Beximco Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beximco Pharmaceuticals (BXMPY) has a Current Ratio of 2.13 as of Dec. 2024. This is 40% above median its historical median of 1.52. Over the past decade, Beximco Pharmaceuticals' Current Ratio has ranged from 1.02 to 3.15.
Is Beximco Pharmaceuticals' Current Ratio too high?
Beximco Pharmaceuticals' current Current Ratio of 2.13 is 40% above median its 10-year median of 1.52. Over the past 10 years, this metric has ranged from a low of 1.02 to a high of 3.15. The Drug Manufacturers industry median Current Ratio is 2.00. Beximco Pharmaceuticals' value of 2.13 is 6.5% above this industry median. Overall, Beximco Pharmaceuticals has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Current Ratio compare to ZTS and UTHR?
Beximco Pharmaceuticals' Current Ratio of 2.13 can be compared against companies in the Drug Manufacturers industry. The industry median Current Ratio is 2.00. Beximco Pharmaceuticals' value of 2.13 is 6.5% above this benchmark. Historically, Beximco Pharmaceuticals' own Current Ratio has ranged from 1.02 to 3.15 over the past decade. While the company's 10-year median is 1.52 vs. the industry median of 2.00, Beximco Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beximco Pharmaceuticals's current Current Ratio of 2.13 is 6.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current Current Ratio is 2.13, which is 40% above median its own 10-year median of 1.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current Current Ratio of 2.13. The current Current Ratio is 2.13, which is 40% above median its 10-year median of 1.52 and 6.5% above the Drug Manufacturers industry median of 2.00. Beximco Pharmaceuticals' overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current Current Ratio is 2.13 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXMPY has been successfully added to your 